Application 064212
- Type
- ANDA
- Sponsor
- TEVA PARENTERAL
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | DAUNORUBICIN HYDROCHLORIDE | DAUNORUBICIN HYDROCHLORIDE | INJECTABLE;INJECTION | EQ 20MG BASE/VIAL | No | No |
| 002 | DAUNORUBICIN HYDROCHLORIDE | DAUNORUBICIN HYDROCHLORIDE | INJECTABLE;INJECTION | EQ 50MG BASE/VIAL | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A064212-001 | DAUNORUBICIN HYDROCHLORIDE | DAUNORUBICIN HYDROCHLORIDE | EQ 20MG BASE/VIAL | INJECTABLE / INJECTION | 1998-06-23 | ||
| A064212-002 | DAUNORUBICIN HYDROCHLORIDE | DAUNORUBICIN HYDROCHLORIDE | EQ 50MG BASE/VIAL | INJECTABLE / INJECTION | 1999-05-03 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A064212-001 | DAUNORUBICIN HYDROCHLORIDE | EQ 20MG BASE/VIAL | INJECTABLE / INJECTION | 1998-06-23 | a50c72e98297… | ||
| 2026-08-01 22:54:32 | 2026-06 | A064212-002 | DAUNORUBICIN HYDROCHLORIDE | EQ 50MG BASE/VIAL | INJECTABLE / INJECTION | 1999-05-03 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Daunorubicin Hydrochloride | DAUNORUBICIN HYDROCHLORIDE | Hisun Pharmaceuticals USA, Inc. | 9705fa12-499e-41a3-8fb4-f6df0858b851 | 2026-01-19 | Boxed warning, Warnings, Adverse reactions | Daunorubicin Hydrochloride DAUNORUBICIN HYDROCHLORIDE |
| daunorubicin hydrochloride | DAUNORUBICIN HYDROCHLORIDE | Meitheal Pharmaceuticals Inc. | ff6b9bd4-8a9f-400f-a0b9-70e25fa8a28f | 2025-05-21 | Boxed warning, Warnings, Adverse reactions | daunorubicin hydrochloride DAUNORUBICIN HYDROCHLORIDE |
| Daunorubicin Hydrochloride | DAUNORUBICIN HYDROCHLORIDE | Hikma Pharmaceuticals USA Inc. | 227784a8-ce68-4dd4-8ac5-a65265969677 | 2024-02-15 | Boxed warning, Warnings, Adverse reactions | Daunorubicin Hydrochloride DAUNORUBICIN HYDROCHLORIDE |
| Daunorubicin Hydrochloride | DAUNORUBICIN HYDROCHLORIDE | Hisun Pharmaceuticals USA, Inc. | f4312095-3c21-296b-e053-2995a90a0d9c | 2023-01-01 | Boxed warning, Warnings, Adverse reactions | Daunorubicin Hydrochloride DAUNORUBICIN HYDROCHLORIDE |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 8359 | ORIG | 1998-06-23 |